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Background: Celastrol, a plant triterpene, is known to play important role in inhibiting proliferation and inducing
apoptosis of gastric cancer cells. In the present study, the mechanism of celastrol on gastric cancer cells apoptosis
was examined.
Methods: We assessed effect of celastrol on NF-κB signaling pathway in gastric cancer cells using western blot
and luciferase reporter assay. The real-time PCR was used to evaluate the effect of celastrol on miR-146a expression,
and miR-146a mimic to evaluate whether over-expression of miR-146a can affect NF-κB activity. Finally, the effect of
miR-146a on celastrol-induced anti-tumor activity was assessed using miR-146a inhibitor.
Results: Celastrol decreased gastric cancer cells viability in a dose-dependent. Celastrol also reduced IκB
phosphorylation, nuclear P65 protein levels and NF-κB activity. Furthermore, Celastrol could increase miR-146a
expression and up-regulation of miR-146a expression could suppress NF-κB activity. More important, down-
regulation of miR-146a expression can reverse the effect of celastrol on NF-κB activity and apoptosis in gastric
cancer cells.
Conclusions: In this study, we demonstrated that the effect of celastrol on apoptosis is due to miR-146a inhibition
of NF-κB activity.
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Gastric cancer is one of the most common cancers
worldwide, which is particularly high in eastern Asia [1].
Despite the advances in current therapeutic approaches
such as surgery, hormone, radio- and chemotherapy,
gastric cancer is still the second most common cause of
death from cancer [2]. Therefore, it is urgent to make
clear the key mechanism of the apoptosis in gastric
cancer as well as establishment of the appropriate
blocking channels is important for the development of
more effective therapies of gastric cancer.
Celastrol is a plant triterpene derived from the root of
Thunder of God Vine and can resist various inflamma-
tory and neurodegenerative disorders [3-5]. It has been
reported that celastrol plays important role in inhibiting
proliferation and inducing apoptosis of wide variety of
human tumor cell types including multiple myeloma,* Correspondence: tzrmyy5211@163.com
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However, its mechanism is not well understood.
MicroRNAs (miRNAs) are a small, non-coding RNA
involved in post-transcriptional gene regulation by
binding to a target site in the 3′-UTR of target mRNAs
[7]. Recent evidence has revealed that the change of
miRNAs expression was associated with tumorigenesis,
which indicated that miRNAs could act as tumor sup-
pressors or oncogenes [8,9]. One of these microRNAs,
miR-146a is down-regulated in gastric cancer, and indu-
ces apoptotic effects by inhibiting G protein-coupled
receptor-mediated activation of NF-κB [10,11]. When
the expression of miR-146a was up-regulated in human
gastric cancer, it was showed to induce cell apoptosis.
The transcription factor NF-κB is activated in tumor-
genic processes including gastric cancer and may be an
important pharmacological target for this disease [12,13].
Activation of NF-κB predominantly occurs via the release
of the p50/p65 heterodimer from the inhibitor of κB (IκB)
complex in the cytosol of the cells. When released from. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cleus and regulates downstream gene expression [14]. In
recent years, more and more evidence indicates that
celastrol can induce apoptosis of various tumors by
inhibiting of NF-κB activation [15,16]. As a result, the aim
of this study was to evaluate whether miR-146a regulating
NF-κB activity is involved in apoptosis of human gastric
cancer cells induced by celastrol.Figure 1 Celastrol repressed viability of gastric cancer cells and NF-κB
resulted in dose- and time-dependent growth inhibition of BGC-823 cells (A),
inhibited phosphorylation of IκB and nuclear p65 content in dose-dependent
cells, SGC-7901 cells and MGC-803 cells in a dose-dependent manner (F). *P <Results
Celastrol repressed cell viability of gastric cancer cells and
NF-κB signaling pathway
The inhibitory effects of celastrol on the growth of gastric
cancer cells and normal gastric epithelial cells were eva-
luated using MTT assays. Celastrol treatment inhibited
the growth of BGC-823, SGC-7901 and MGC-803 cells in
a dose- and time-dependent manner (Figure 1A, 1B andsignaling pathway. Exposure to various concentrations of celastrol
SGC-7901 cells (B), MGC-803 cells (C) and GES-1 cells (D). Celastrol
manner (E). Celastrol decreased NF-κB transcriptional activity in BGC-823
0.05, indicate significant differences from the respective control groups.
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0.989 μM (BGC-823 cells), 0.798 μM (SGC-7901 cells)
and 1.98 μM (MGC-803 cells). Normal gastric epithelial
cells showed more resistance to the cytotoxicity effect of
celastrol. And the IC 50 value at 72 h was 8.16 μM for
GES-1 cells (Figure 1D).
Next, we wanted to determine whether the NF-κB
pathway was inhibited by celastrol in gastric cancer
cells. Therefore, phosphorylation of IκB was inves-
tigated as a potential response to treatment with
celastrol. As shown by western blot analysis in Figure 1E,
celastrol inhibited phosphorylation of IκB in a dose-
dependent manner in BGC-823 cells, SGC-7901 cells and
MGC-803 cells.
It is well known that the phosphorylation and degrad-
ation of IκB can result in the release of NF-κB complex
followed by its rapid translocation into the nucleus
[17]. To investigate the nuclear entry of NF-κB
complex, the p65 content was measured by western
blot in BGC-823, SGC-7901 and MGC-803 cells. Treat-
ment with celastrol could inhibit p65 entry into the nu-
cleus (Figure 1E). The inhibition of NF-κB signaling
pathway by celastrol was also determined by the ob-
servation of the transcriptional activity of NF-κB. As
shown in Figure 1F, the treatment of BGC-823, SGC-
7901 and MGC-803 cell with celastrol strongly
inhibited the NF-κB transcriptional activity in a dose-
dependent manner.Figure 2 Celastrol stimulates miR-146a expression in gastric cancer ce
celastrol treatment for 12 h in BGC-823, SGC-7901 and MGC-803 cells. *P <Celastrol increases miR-146a expression
To further identify the mechanism for celastrol inhi-
bition of BGC-823, SGC-7901 and MGC-803 cells
growth, we performed real-time PCR to detect miR-146a
expression after treated with 2 μM of celastrol for 12 h.
As shown in Figure 2, celastrol treatment significantly in-
creased the expression of miR-146a in these cells (P < 0.01).
However, celastrol can not significantly induce miR-146a
expression in GES-1 cells.
Up-regulation of miR-146a expression can inhibit NF-κB
activity
To determine whether miR-146a can regulate signaling
pathway in gastric cancer cells, we investigated the
modulation of phosphorylation of IκB in cells trans-
fected miR-146a mimic by western blot. The result of
real-time PCR revealed that miR-146a mimic can signifi-
cantly increase the expression of miR-146a in BGC-823,
SGC-7901 and MGC-803 cells (P < 0.01) (Figure 3A),
suggesting that miR-146a mimic is efficiently introduced
into the cells and acts to up-regulate miR-146a expres-
sion. Furthermore, transfection of miR-146a mimic
decreased phosphorylation of IκB and nuclear P65 as
shown in Figure 3B.
We also measured the transcriptional activity of NF-
κB using Luciferase reporter assay. Figure 3C showed
that up-regulation of miR-146a expression decreased
NF-κB activity, which was similar to Bay.lls. The expression of miR-146a was significantly increased after
0.05 vs. control group.
Figure 3 Up-regulation of miR-146a expression can inhibit NF-κB activity in BGC-823, SGC-7901 and MGC-803 cells. The real-time PCR
revealed that miR-146a mimic significantly increased the expression of miR-146a (A). Western blot showed that transfected miR-146a mimic
decreased phosphorylation of IκB and nuclear p65 level (B). The luciferase reporter assay revealed that transfected miR-146a mimc significantly
repressed NF-κB transcriptional activity (C). *P < 0.05, indicate significant differences from the respective control groups.
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celastrol on NF-κB activity and apoptosis
In order to evaluate the role of miR-146a in the effect of
celastrol on inhibition of BGC-823, SGC-7901 and
MGC-803 cells apoptosis, we treated cells with celastrol
after transfected with miR-146a inhibitor. As shown in
Figure 4A, miR-146a inhibitor can significantly decrease
the expression of miR-146a in BGC-823, SGC-7901 and
MGC-803 cells (P < 0.01). Interestingly, we found that
celastrol treatment inhibited transcriptional activity of
NF-κB, which can be restored by inhibition of miR-146a
expression (Figure 4B). In addition, the number of cells
that underwent apoptosis significantly increased after
treated with 2 μM celastrol. Moreover, the celastrol
induced apoptosis was attenuated by miR-146a inhibitorin BGC-823, SGC-7901 and MGC-803 cells (Figure 4C).
Furthermore, BGC-823, SGC-7901 and MGC-803 cells
growth was increased in celastrol-treated cells after
transfected miR-146a inhibitor (Figure 4D).
Discussion
The present report describes the molecular mechanism
of growth arrest induced by celastrol in human gastric
cancer cells. Celastrol inhibited proliferation of BGC-823,
SGC-7901 and MGC-803 cells, but had little effect
on GES-1 cells, indicating celastrol induces selective
cytotoxicity in cells. This triterpene caused the down-
regulation of phosphorylation of IκB and nuclear P65
protein levels, and it inhibited transcriptional activity of
NF-κB. Celastrol increased miR-146a expression in gastric
Figure 4 Down-expression of miR-146a can reverse the effect of celastrol on NF-κB activity and apoptosis. The real-time PCR revealed
that miR-146a inhibitor can significantly decrease the expression of miR-146a in BGC-823, SGC-7901 and MGC-803 cells (A). After transfected with
100 nmol/L of miR-146a inhibitor, the cells were treated with 2 μM celastrol for 6 h. miR-146a inhibitor significantly increased NF-κB transcriptional
activity in BGC-823, SGC-7901 and MGC-803 cells after celastrol treatment (B). Flow-cytometric analysis showed that miR-146a inhibitor significantly
decreased the apoptosis of BGC-823, SGC-7901 and MGC-803 cells induced with celastrol (C). After transfected with 100 nmol/L of miR-146a
inhibitor, the cells were treated with 2 μM celastrol for 72 h. MTT revealed that miR-146a inhibitor significantly decreased the effect of celastrol on
inhibition of BGC-823, SGC-7901 and MGC-803 cells growth (D). *P < 0.05, indicate significant differences from the respective control groups.
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cantly decrease NF-κB activity. Further, it induced apop-
tosis of BGC-823, SGC-7901 and MGC-803 cells, which
can be reversed by down-regulation of miR-146a expres-
sion. We also found that celastrol inhibited NF-κB activity
could also be restored by down-regulation of miR-146a
expression.
Increasing evidence showed that celastrol can inhibit
tumor cell proliferation and induce apoptosis through
inhibition of NF-kB activity [18,19]. Activation of theclassical pathway of NF-κB involves the phosphorylation
and subsequent degradation of IκBα, leading to the re-
lease and translocation of NF-κB to the nucleus [20].
Our studies showed that in gastric cancer cells, celastrol
was observed to decrease phosphorylation of IκB and
subsequent inhibition of NF-κB signaling pathway,
exhibiting an anti-tumor potential. More important, the
IC 50 value at 72 h after treatment was 0.989 μM for
BGC-823 cells 0.798 μM for SGC-7901 cells and 1.98 μM
for MGC-803 cells, but 8.16 μM for GES-1 cells. These
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killing gastric cancer cells without destruction to the
normal cells, which is in agreement with the previous
reports [6].
To further clarify the mechanism involved in the
inhibition of viability of gastric cancer cells, we investi-
gated the effect of celastrol on the expression of
miR-146a. Prior study indicated that miR-146a is down-
regulated in gastric cancer tissue samples and cell lines
and overexpression of miR-146a could induce apoptosis
of cancer cells [10,11]. As a result, miR-146a may be
a promising target for treatment of gastric cancer.
Interestingly, celastrol was observed to up regulate the
expression of miR-146a in BGC-823, SGC-7901 and
MGC-803 cells but not in GES-1 cells, which indicated
that miR-146a may be involved in growth inhibition
induced by celastrol. This hypothesis was confirmed that
inhibition of miR-146a expression can reverse the effect
of celastrol on apoptosis and growth inhibition of cancer
cells.
We also found that over-expression of miR-146a could
reduce phosphorylation of IκB and nuclear P65 protein
levels, leading to inhibition of NF-κB transcriptional ac-
tivity. Moreover, inhibition of miR-146a expression can
reverse NF-κB activity repression by celastrol. According
to these results, we draw a conclusion that celastrol sup-
presses NF-κB activity by enhancing miR-146a expression.
In summary, we established a primary relationship be-
tween celastrol and apoptosis in BGC-823, SGC-7901
and MGC-803 cells here. Furthermore, we explored the
molecular mechanisms of celastrol-induced apoptosis in
gastric cancer cells. These results suggest that celastrol
might be an effective drug to treat human gastric cancer.
Materials and methods
Chemicals and reagents
Dulbecco’s modified Eagle’s medium (DMEM), sodium
pyruvate were from Gibco-BRL (Rockville, MD, USA).
Fetal bovine serum (FBS) was from PAA Laboratories
(GmbH, Linz, Austria). Celastrol was purchased from
Alexis Biochemicals (San Diego, CA). Bay 11–7082 (Bay)
and dimethylthiazoly-2, 5-diphenyltetrazolium bromide
(MTT) were obtained from Sigma Aldrich. Mouse anti-
phospho-IκB (Ser32/36) antibody was obtained from Cell
Signaling Technology (Beverly, MA, USA). Mouse anti-β-
actin and goat anti-Lamin B antibodies were purchased
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
Annexin V-EGFP ⁄ PI Apoptosis Detection Kit was from
KeyGen (Nanjing, China). The Detergent Compatible
(DC) Protein Assay kit was purchased from Bio-Rad
Laboratories (Hercules, CA, USA). The miRNeasy Mini
kit, the miScript Reverse Transcription kit and the
miScript SYBR Green PCR kit were purchased from
Qiagen (Hilden, Germany).Cell culture
Human gastric adenocarcinoma cell line BGC-823 cells
and SGC-7901 cells, and gastric mucinous adenocarcinoma
cell line MGC-803 were purchased from the Shanghai
Institute of Cytobiology in Chinese Academy of Sciences.
Human normal gastric epithelial cell line GES-1 was ob-
tained from the Institute of Oncology in Beijing University.
The cells were grown in DMEM medium supplemented
with 10% FBS, 100 units/ml penicillin and 100 μg/mL
streptomycin, and routinely passaged at 3-day intervals. All
cell lines were maintained at 37°C in a humidified incubator
containing 5% CO2 and treated with celastrol (dissolved in
DMSO) in complete DMEM medium. To obtain reliable
results, the final concentration of DMSO in the culture
medium was kept less than 0.1%.
MTT assay
Cell viability was determined using MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide as-
says. Briefly, the cells were seeded in 96-well dishes at 1 ×
104 cells per well, and treated with different concentra-
tions of celastrol. Then each well was supplemented with
10 μL MTT and incubated for 4 h at 37°C. The medium
was then removed, and 150 μL DMSO (Sigma Aldrich)
was added to solubilize the MTT formazan. The optical
density was read at 490 nm. The inhibition rate was calcu-
lated as follows: inhibition rate = [(mean control absorb-
ance - mean experimental absorbance) ⁄ mean control
absorbance] × 100 (%). To evaluate the effect of celastrol
on cellular growth, the concentration that caused 50%
growth inhibition (IC 50) was calculated by the modified
Karbers method according to the formula: IC50 = log− 1
[Xk − i (∑P − 0.5)], in which Xk represents the celastrol of
the highest drug concentration; i is that of ratio of adja-
cent concentration; and ∑P is the sum of the percentage
of growth inhibition at various concentrations [21].
Flow cytometry analysis
This assay is based on the translocation of phospha-
tidylserine from the inner leaflet of the plasma mem-
brane to the cell surface in early apoptotic cells [22].
Briefly, cells were resuspended in a binding buffer. Next,
annexin V-EGFP and PI were added and the solution
was incubated at room temperature for 15 min in the
dark, followed by assay on FACScan (Becton Dickin-son).
The percentage of apoptosis was computed using Cell-
Quest software (Becton Dickinson).
Oligonucleotides and Cell Transfection
miR-146a was knocked down or overexpressed by trans-
fection with miRNA inhibitor or miRNA mimic using
siPort Neo-FX (Ambion) according to the manufacturer’s
recommendations. miR-146a mimics (5′-UGAGAACUG
AAUUCCAUGGGUU-3′), miR-146a inhibitor (5′-AACC
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inhibitors (NC, 5′-UUGUACUACACAAAAGUACUG-3′)
were synthesized by RIBOBIO (Ribobio Co. Ltd,
Guangzhou, China). All of the oligonucleotides were
transfected at a final concentration of 100 nM. BGC-823,
SGC-7901 and MGC-803 cells were transfected with miR-
146a inhibitor or mimic using siPort Neo-FX (Ambion)
according to the manufacturer’s recommendations.
Quantitative real-time PCR (Q-PCR) analysis of miRNA
expression
Approximately 5 × 106 cells were treated without (control)
or with celastrol for 12 h. miRNAs were isolated and puri-
fied using Trizol reagent (Invitrogen, USA), according to
manufacturer’s protocol. The miR-146a level was quanti-
fied by real-time PCR using TransStartTM SYBR Green
qPCR Supermix (TransGen Biotech, Beijing, China), and
with U6 small nuclear RNA as an internal normalized ref-
erence. For miR-146a, the primers were as follows: for-
ward, 5′- GCCGATTGGAGTGGTAAAC-3′ and reverse,
5′-AAGACCCCTCGTTGCAGT-3′. For U6, the primers
were as follows: forward, 5′-CTCGCTTCGGCAGCACA-
3′ and reverse, 5′-AACGCTTCACGAATTTGCGT-3′.
Luciferase reporter assay
The reporter plasmid, pNF-κB-luc, containing the κB-
enhancer consensus sequences [(TGGGGACTTTCC
GC) × 5] and NF-κB-dependent firefly luciferase gene was
purchased from Stratagene (La Jolla, CA, USA). BGC-823,
SGC-7901 and MGC-803 cells were transiently trans-
fected with two plasmids (pNF-κB-luc plasmid and β-
galactosidase) using the LipofectAMINE Plus regent. Cells
were passaged on 24-wells plate the day prior to transfec-
tion to achieve 80%-85% confluence on the following day.
Twelve hours after transfection, cells were incubated for an
additional 24 h in medium containing different con-
centration of celastrol and harvested for luciferase reporter
assays. Luciferase activity was measured with a lumi-
nometer (TD-20/20; Turner Designs, CA, USA) using the
Luciferase Assay System. β-Galactosidase activity was de-
tected to normalise any variations in the transfection
efficiency.
Western blot analysis
Total protein was extracted using a lysis buffer con-
taining 50 mmol/l Tris–HCl, pH 7.4; 1% NP-40; 150
mmol/l NaCl; 1 mmol/l EDTA; 1 mmol/l phenylmethyl-
sulfonyl fluoride; and complete proteinase inhibitor
mixture (one tablet per 10 ml; Roche Molecular Bio-
chemicals, Indianapolis, IN, USA). The cytosol and
nuclear extracts were prepared by NE-PER nuclear and
cytoplasmic extraction reagents (Pierce Biotechnology,
Rockford, IL, USA) according to the manufacturer’s
instructions. Protein concentration in the cell lysate wasquantified using the DC protein assay kit (Bio-Rad).
Then, Western blot analysis was performed. β-actin and
Lamin B were used as internal controls for the total and
nuclear extracts, respectively.
Statistical analysis
Statistical analysis was performed with statistical analysis
software SPSS 13.0 software. Statistical analyses were
performed using either an analysis of variance (ANOVA)
or Student’s t-test. Data were expressed as mean ± stand-
ard deviation. P < 0.05 was considered to be significant.
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